

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION

APRIL 2014

GUIDELINES

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION

APRIL 2014

WHO Library Cataloguing-in-Publication Data

Guidelines for the screening, care and treatment of persons with hepatitis C infection.

1. Hepatitis C – prevention and control. 2. Hepatitis C – diagnosis. 3. Hepatitis C – drug therapy.
4. Guideline. I. World Health Organization.

ISBN 978 92 4 154875 5

(NLM classification: WC 536)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

Design and layout: blossoming.it

CONTENTS

ACKNOWLEDGEMENTS	7
ABBREVIATIONS AND ACRONYMS	10
GLOSSARY OF TERMS	12
EXECUTIVE SUMMARY	13
1. SCOPE AND OBJECTIVES	23
2. BACKGROUND	25
2.1 Epidemiology of hepatitis C	25
2.2 Hepatitis C virus	29
2.3 Natural history of HCV infection	30
2.4 Prevention of HCV infection	31
2.5 Screening for HCV infection	34
2.6 Care of patients with HCV infection	34
2.7 Treatment of patients with HCV infection	35
2.8 Cost-effectiveness of treatment	35
3. GUIDING PRINCIPLES	37
3.1 Human rights	37
3.2 Access to health care	37
3.3 Service provision	37
3.4 Integrated health care	38
4. METHODS	39
5. RECOMMENDATIONS ON SCREENING	43
5.1 Screening to identify persons with HCV infection	43
5.2 When to confirm a diagnosis of chronic HCV infection	48
6. RECOMMENDATIONS ON CARE OF PEOPLE INFECTED WITH HCV	51
6.1 Screening for alcohol use and counselling to reduce moderate and high levels of alcohol intake	51
6.2 Assessing the degree of liver fibrosis and cirrhosis	56
7. RECOMMENDATIONS ON TREATMENT	63
7.1 Assessment for HCV treatment	63
7.2 Treatment with pegylated interferon and ribavirin	67
7.3 Treatment with telaprevir or boceprevir	70

7.4 Introduction to recommendations concerning sofosbuvir and simeprevir	74
7.5 Treatment with sofosbuvir	74
7.6 Treatment with simeprevir	78

8. CLINICAL CONSIDERATIONS 80

8.1 Monitoring for toxicity	84
8.2 Dose modification	86
8.3 Monitoring for efficacy	87

9. SPECIAL CONSIDERATIONS FOR SPECIFIC POPULATIONS 89

9.1 People who inject drugs	89
9.2 Persons with HIV and HCV coinfection	90
9.3 Children and adolescents	95
9.4 Persons with liver cirrhosis	96
9.5 Persons with HBV and TB coinfection	96
9.6 Persons with renal impairment	97

10. OPERATIONAL AND IMPLEMENTATION ISSUES 98

10.1 Service planning	98
10.2 Service delivery	99
10.3 Future considerations	100
10.4 Dissemination, monitoring and implementation of the Guidelines	101

11. REFERENCES 102

APPENDICES

All appendices will be made available on the WHO, HIV website, along with the entire report.

Appendix 1: PICO Questions

Appendix 2: Example of GRADE decision-making table

Appendix 3: Systematic reviews and evidence summaries

Appendix 4: Decision-making tables

Appendix 5: Technical report on monitoring during treatment

Appendix 6: Summary of declared interests

ACKNOWLEDGEMENTS

Many professionals from a range of backgrounds and specialties have contributed to the development of this guidance. WHO is sincerely grateful for their time and support.

Guidelines Development Group

The chairs of the Guideline Development Group were Bryce Smith (Centers for Disease Control and Prevention, USA) and Yngve Falck-Ytter (Case Western Reserve University, USA). The following experts served on the Guidelines Development Group:

Ruth Birgin (Women and Harm Reduction International Network, Australia); Scott Bowden (Victorian Infectious Diseases Reference Laboratory, Australia); Vladimir Chulanov (Central Research Institute of Epidemiology, Reference Center for Viral Hepatitis, Russia); Wahid Doss (National Hepatology and Tropical Medicine Research Institute, Egypt); Nicolas Durier (TREAT Asia/amfAR – Foundation for AIDS Research, Thailand); Serge Paul Eholie (Service des Maladies Inféctieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Côte d'Ivoire); Jorge Enrique González (National Reference Laboratory, Argentina); Charles Gore (World Hepatitis Alliance, Switzerland); Manal Hamdy El-Sayed (Faculty of Medicine, Ain Shams University, Egypt); Koji Ishii (National Institute of Infectious Diseases, Japan); S. M. Wasim Jafri (The Aga Khan University, Pakistan); Maud Lemoine (Medical Research Council, The Gambia Unit, Imperial College London, UK); Anna Lok (University of Michigan and American Association for the Study of Liver Diseases, USA); Endale Kassa Lulu (Addis Ababa University, Ethiopia); Isabelle Andrieux-Meyer (Médecins sans Frontières, Switzerland); Masashi Mizokami (National Institute of Infectious Diseases, Japan); Dasha Ocheret (Eurasian Harm Reduction Network, Lithuania); Frederick Okoth (Kenya Medical Research Institute, Kenya); John Parry (Public Health England, UK); Nahum Méndez-Sánchez (Medica Sur Clinic & Foundation, Mexico); Shiv Kumar Sarin (Institute of Liver and Biliary Sciences, India); Umesh Sharma (Asian Network of People who Use Drugs, India/Australia); Bernd Stalenkrantz (International Network of People who Use Drugs, Sweden); Tracy Swan (Treatment Action Group, USA); Lynn Taylor (Brown University, USA); Xiaochun Wang (National Centre for AIDS/STD Prevention and Control, China)

External peer review group

We thank the following experts for reviewing the final guideline document and providing valuable input.

Jude Byrne (The International Network of People who Use Drugs, Australia); Chris Cooper (University of Ottawa, Canada); Imam Waked (National Liver Institute, Egypt); Mark Thursz (Imperial College, UK); Liudmyla Maistat (International HIV/AIDS Alliance in Ukraine, Ukraine); Ahmed Khatib (Ministry of Health and Social Welfare, Zanzibar); Pauline Londeix (Act Up-Basel, Europe); Niklas Luhmann (Médecins du Monde, France); Dorthe Raben (University of Copenhagen, Denmark)

Steering Committee

The following WHO staff formed the Guidelines Steering Committee:

Stefan Wiktor, Tim Nguyen (Global Hepatitis Programme); Nicolas Clark (Management of Substance Abuse); Philippa Easterbrook, Marco Vitoria (HIV/AIDS Department); Anita Sands (Essential Medicines and Health Products).

We extend our gratitude to the following staff for technical input, guidance on the WHO guidelines development process, and support to the steering committee: Susan Norris and Myriam Felber (Guidelines Review Committee secretariat); Charles Penn (Department of Epidemic and Pandemic Diseases); Irina Eramova (European Regional Office), and Nathan Ford, Sarah Hess, and Naoko Obara (HIV/AIDS Department).

Temporary advisors

We would like to credit the following researchers for developing the initial scoping document and conducting all systematic reviews, evidence profiles and GRADE tables:

Margaret Hellard – principal team leader, Joe Doyle – senior reviewer (Burnet Institute, Melbourne, Australia); Sharon Hutchinson, Esther Aspinall, David Goldberg (Glasgow Caledonian University and Health Protection Scotland, UK).

We appreciate the contribution from the following people for providing technical presentations and sharing their research with the Guidelines Development Group:

Louise Longworth (Brunel Institute, UK); Natasha Martin (University of Bristol, UK); Emma Thomson (University of Glasgow/Imperial College London, UK); Emmanuel Tsochatzis (Royal Free Hospital and UCL Institute, UK); Yazdan Yazdapanah (University of Paris, France).

Chairpersons and methodologists

We would like to acknowledge the work of Bryce Smith and Yngve Falck-Ytter for chairing the Guidelines Development Group. We thank Rebecca Morgan and Yngve Falck-Ytter for serving as methodologists who oversaw the development of the PICO questions and the conduct of the systematic reviews, and reviewed the evidence profiles and GRADE tables.

The first drafts of the guidelines were written by Emma Thomson. Drafts were reviewed and inputs provided by members of the Guideline Development Group, peer reviewers, and WHO Secretariat staff. The final draft was edited by Bandana Malhotra.

Overall coordination

Stefan Wiktor

Funding

Funding for the development of these guidelines was provided by the US Centers for Disease Control and Prevention and the Ministry of Health, Labour and Welfare of Japan.

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>